Bill & Melinda Gates Medical Research Institute
- Country
- 🇺🇸United States
- Ownership
- Private
- Established
- 2017-01-01
- Employees
- 101
- Market Cap
- -
- Website
- https://www.gatesmri.org
Clinical Trials
16
Trial Phases
3 Phases
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (15 trials with phase data)• Click on a phase to view related trials
A Trial in Healthy Adult Participants to Evaluate the Safety, Tolerability, and Behavior in the Body of TBD11
- First Posted Date
- 2024-11-27
- Last Posted Date
- 2025-08-06
- Lead Sponsor
- Gates Medical Research Institute
- Target Recruit Count
- 108
- Registration Number
- NCT06707142
- Locations
- 🇺🇸
Celerion, Lincoln, Nebraska, United States
Study To Evaluate Safety, Tolerability, and Pharmacokinetics of MAM01 in African Population
- Conditions
- Healthy Volunteers
- Interventions
- Drug: MAM01 300 mg SCDrug: MAM01 300 mg IMDrug: MAM01 2000 mg IVDrug: MAM01 190 mg SCDrug: MAM01 225 mg SCDrug: MAM01 150 mg SCDrug: MAM01 150 mg IMDrug: MAM01 150 mg IVDrug: Placebo SCDrug: Placebo IMDrug: Placebo IV
- First Posted Date
- 2024-05-10
- Last Posted Date
- 2025-08-07
- Lead Sponsor
- Gates Medical Research Institute
- Target Recruit Count
- 123
- Registration Number
- NCT06408857
- Locations
- 🇺🇬
JCRC-Joint Clinical Research Centre, Kampala, Uganda
🇺🇬IDRC-Infectious Disease Research Collaboration, IDRC Tororo Hospital Station Road, Tororo, Uganda
Study to Assess Efficacy and Safety of M72/AS01E-4 Mycobacterium Tuberculosis (Mtb) Vaccine in Adolescents and Adults
- Conditions
- Tuberculosis
- Interventions
- Biological: PlaceboBiological: M72/AS01E-4 Mycobacterium tuberculosis investigational vaccine
- First Posted Date
- 2023-10-02
- Last Posted Date
- 2025-08-21
- Lead Sponsor
- Gates Medical Research Institute
- Target Recruit Count
- 20081
- Registration Number
- NCT06062238
- Locations
- 🇮🇩
2201-Gates MRI Investigational Site, Bandung, Indonesia
🇮🇩2204-Gates MRI Investigational Site, Depok, Indonesia
🇮🇩2202-Gates MRI Investigational Site, Jakarta, Indonesia
Efficacy and Safety Evaluation of Two to Four Months of Treatment With the Combination Regimens of DBOS and PBOS in Adults With Pulmonary Tuberculosis
- Conditions
- Pulmonary Tuberculosis
- Interventions
- Drug: Pretomanid, Bedaquiline, OPC-167832, and Sutezolid (PBOS)Drug: Delamanid, Bedaquiline, OPC-167832, and Sutezolid (DBOS)Drug: Isoniazid, Rifampicin, Pyrazinamide, Ethambutol (HRZE)
- First Posted Date
- 2023-08-02
- Last Posted Date
- 2025-02-25
- Lead Sponsor
- Bill & Melinda Gates Medical Research Institute
- Target Recruit Count
- 93
- Registration Number
- NCT05971602
- Locations
- 🇵🇭
Tropical Disease Foundation, Makati, Philippines
🇵🇭Lung Center of the Philippines, Quezon City, Philippines
🇵🇭Silang Specialist Medical Center, Silang, Philippines
Impact of Bi-26 Supplementation on Weight Gain in Underweight Infants
- Conditions
- UnderweightPaediatrics
- First Posted Date
- 2023-07-19
- Last Posted Date
- 2025-03-04
- Lead Sponsor
- Bill & Melinda Gates Medical Research Institute
- Target Recruit Count
- 40
- Registration Number
- NCT05952076
- Locations
- 🇵🇰
Medical Facility A, Islamabad, Islamabad Capital Territory, Pakistan
🇵🇰Medical Facility B, Islamabad, Islamabad Capital Territory, Pakistan
🇵🇰Medical Facility C, Islamabad, Islamabad Capital Territory, Pakistan
- Prev
- 1
- 2
- 3
- Next